Beldhuis, I. E. http://orcid.org/0000-0002-3679-168X
ter Maaten, J. M.
Figarska, S. M.
Damman, K.
Pang, P. S.
Greenberg, B.
Davison, B. A.
Cotter, G.
Severin, T.
Gimpelewicz, C.
Felker, G. M.
Filippatos, G.
Teerlink, J. R.
Metra, M.
Voors, A. A.
Funding for this research was provided by:
Novartis
Article History
Received: 27 October 2022
Accepted: 19 December 2022
First Online: 19 January 2023
Declarations
:
: B. Greenberg received honoraria from Novartis for participation in the Executive Committee for studies of serelaxin in acute heart failure. B. Davison is an employee of Momentum Research, Inc., which has received grants from Abbott Laboratories, Amgen, Celyad, Cirius Therapeutics Inc., Corteria Pharmaceuticals, Roche Diagnostics Inc., Sanofi, Windtree Therapeutics Inc. and XyloCor Therapeutics. G. Cotter is an employee of Momentum Research, Inc. which has received grants from Abbott Laboratories, Amgen, Celyad, Cirius Therapeutics Inc., Corteria Pharmaceuticals, Roche Diagnostics Inc., Sanofi, Windtree Therapeutics Inc. and XyloCor Therapeutics. M Felker has received research grants from NHLBI, American Heart Association, Amgen, Bayer, BMS, Merck, Cytokinetics, and CSL-Behring; he has acted as a consultant to Novartis, Amgen, BMS, Cytokinetics, Medtronic, Cardionomic, Boehringer-Ingelheim, American Regent, Abbott, Astra-Zeneca, Reprieve, Myovant, Sequana, Windtree Therapuetics, and Whiteswell, and has served on clinical endpoint committees/data safety monitoring boards for Amgen, Merck, Medtronic, EBR Systems, V-Wave, LivaNova, Siemens, and Rocket Pharma. G. Gimpelewicz and T. Severin are Novartis employees. G. Filippatos is a committee member and/or has received lecture fees from Bayer, Boehringer Ingelheim, Vifor, Servier, Novartis, Medtronic, and Amgen. All other authors have no disclosures to report. The RELAX-AHF2 trial was sponsored by Novartis Pharma.